- Home
- TBBK vs RCKT Comparison
TBBK vs RCKT Comparison
Compare TBBK & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBBK
- RCKT
- Stock Information
- Founded
- TBBK 1999
- RCKT 1999
- Country
- TBBK United States
- RCKT United States
- Employees
- TBBK N/A
- RCKT N/A
- Industry
- TBBK Major Banks
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- TBBK Finance
- RCKT Health Care
- Exchange
- TBBK Nasdaq
- RCKT Nasdaq
- Market Cap
- TBBK 2.4B
- RCKT 326.4M
- IPO Year
- TBBK 2004
- RCKT N/A
- Fundamental
- Price
- TBBK $58.90
- RCKT $2.90
- Analyst Decision
- TBBK Buy
- RCKT Buy
- Analyst Count
- TBBK 3
- RCKT 13
- Target Price
- TBBK $65.33
- RCKT $18.50
- AVG Volume (30 Days)
- TBBK 498.6K
- RCKT 4.3M
- Earning Date
- TBBK 07-24-2025
- RCKT 08-04-2025
- Dividend Yield
- TBBK N/A
- RCKT N/A
- EPS Growth
- TBBK 20.50
- RCKT N/A
- EPS
- TBBK 4.42
- RCKT N/A
- Revenue
- TBBK $502,282,000.00
- RCKT N/A
- Revenue This Year
- TBBK N/A
- RCKT N/A
- Revenue Next Year
- TBBK $6.71
- RCKT N/A
- P/E Ratio
- TBBK $13.33
- RCKT N/A
- Revenue Growth
- TBBK 10.02
- RCKT N/A
- 52 Week Low
- TBBK $37.65
- RCKT $2.19
- 52 Week High
- TBBK $65.84
- RCKT $26.98
- Technical
- Relative Strength Index (RSI)
- TBBK 71.00
- RCKT 41.69
- Support Level
- TBBK $55.58
- RCKT $2.40
- Resistance Level
- TBBK $51.43
- RCKT $2.70
- Average True Range (ATR)
- TBBK 1.67
- RCKT 0.21
- MACD
- TBBK 0.65
- RCKT 0.15
- Stochastic Oscillator
- TBBK 91.55
- RCKT 73.53
About TBBK The Bancorp Inc
The Bancorp Inc is a financial holding company. The Company's operations are classified under three segments: fintech, specialty finance (three sub-segments), and corporate. The fintech segment includes the deposit balances and non-interest income generated by prepaid, debit, and other card-accessed accounts, ACH processing, and other payments-related processing. It also includes loan balances and interest and non-interest income from credit products generated through payment relationships; Specialty finance includes REBL (real estate bridge lending) comprised of apartment building rehabilitation loans, and Others; Corporate includes the Company's investment securities, corporate overhead, and expenses which have not been allocated to segments.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.